An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 9, 2013, Pages 6373-6381

  Park, Paul J ^a   Antoine, Thessicar E ^a   Farooq, Asim V ^a   Valyi Nagy, Tibor ^a   Shukla, Deepak ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acyclovir; Heparan sulfate; Herpes simplex keratitis

Indexed keywords

ACICLOVIR; G2 PEPTIDE; SYNDECAN 1; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EYE INFECTION; FLUORESCENCE MICROSCOPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SPECTROPHOTOMETRY; SWINE; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS REPLICATION; WESTERN BLOTTING;

ACYCLOVIR; HEPARAN SULFATE; HERPES SIMPLEX KERATITIS;

ACYCLOVIR; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HERPESVIRUS 1, HUMAN; IMMUNOHISTOCHEMISTRY; KERATITIS, HERPETIC; VERO CELLS;

EID: 84884742628     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12832     Document Type: Article

References (24)

1. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012;57: 448-462.
2. Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex, Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107:1155-1159.
3. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol. 2003;121:108-112.
4. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea. 2001;20:1-13.
5. Imperia PS, Lazarus HM, Dunkel EC, Pavan-Langston D, Geary PA, Lass JH. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res. 1988;9:263-272.
6. Lass JH, Langston RH, Foster CS, Pavan-Langston D. Antiviral medications and corneal wound healing. Antiviral Res. 1984;4: 143-157.
7. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo. J Biol Chem. 2011;286:25406-25415.
8. 0, inhibits herpes simplex virus type 1 ocular infection in vivo. Invest Ophthalmol Vis Sci. 2013;54:1070-1079.
9. Brandt CR, Akkarawongsa R, Altmann S, et al. Evaluation of a thetadefensin in a Murine model of herpes simplex virus type 1 keratitis. Invest Ophthalmol Vis Sci. 2007;48:5118-5124.
10. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/ NGF receptor family. Cell. 1996;87:427-436.
11. Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
12. Shah A, Farooq AV, Tiwari V, Kim MJ, Shukla D. HSV-1 infection of human corneal epithelial cells: receptor-mediated entry and trends of re-infection. Mol Vis. 2010;16:2476-2486.
13. Roller RJ, Herold BC. Characterization of a BHK(TK-) cell clone resistant to postattachment entry by herpes siplex virus types 1 and 2. J Virol. 1997;71:5805-5813.
14. Kabosova A, Kramerov AA, Aoki AM, Murphy G, Zieske JD, Ljubimov AV. Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp Eye Res. 2003;77:211-217.
15. Alekseev O, Tran AH, Azizkhan-Clifford J. Ex vivo organotypic corneal model of acute epithelial herpes simplex virus type 1 infection. J Vis Exp. 2012;69:e3631.
16. Xiao J, Natarajan K, Rajala MS, Astley RA, Ramadan RT, Chodosh J. Vitronectin: a possible determinant of adenovirus type 19 tropism for human corneal epithelium. Am J Ophthalmol. 2005;140:363-369.
17. Boutell C, Everett RD. Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J Gen Virol. 2013;94:465-481.
18. Karasneh GA, Ali M, Shukla D. An important role for syndecan-1 in herpes simplex virus type-1 induced cell-to-cell fusion and virus spread. PLoS One. 2011;6:e25252
19. Wilson SS, Fakioglu E, Herold BC. Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther. 2009; 7:559-568.
20. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother. 1997;41:1521-1530.
21. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother. 2005;49:1055-1059.
22. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study. Antiviral Res. 2007;73:147-150.
23. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-128.
24. WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol. 1989;63:52-58.